Literature DB >> 24662778

Progression of myopic maculopathy after treatment of choroidal neovascularization.

Cláudia L Farinha1, Alda S Baltar, Sandrina G Nunes, João P Figueira, Isabel A Pires, Maria L Cachulo, Rufino M Silva.   

Abstract

PURPOSE: To evaluate the long-term progression of myopic maculopathy and functional outcome after treatment of myopic choroidal neovascularization (CNV) with photodynamic therapy (PDT) and/or intravitreal ranibizumab (IVR).
METHODS: Retrospective study with a cross-sectional evaluation. Eyes were assigned to 4 groups (PDT, IVR, PDT + IVR, dry myopic maculopathy) and evaluated with best-corrected visual acuity, color fundus photography and spectral-domain optical coherence tomography. Chorioretinal atrophy progression was quantified.
RESULTS: Fifty-four eyes were included with a mean follow-up of 80.6 ± 28.0 months. The prevalence of diffuse, patchy and macular atrophy increased during the follow-up, in contrast with tessellated fundus, lacquer cracks and active CNV. Progression of macular atrophy was significant in the 3 treatment groups (p < 0.05) and predictive of visual acuity. It depended on age, degree of myopia and presence of staphyloma, but not on the type of treatment.
CONCLUSIONS: The long-term functional outcome of eyes with myopic CNV is more dependent on the progression of macular atrophy, and not on the type of treatment.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24662778     DOI: 10.1159/000357290

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  9 in total

1.  Choroidal neovascularization secondary to pathological myopia-macular Bruch membrane defects as prognostic factor to anti-VEGF treatment.

Authors:  João Coelho; André Ferreira; Ana Carolina Abreu; Sílvia Monteiro; Maria João Furtado; Miguel Gomes; Miguel Lume
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-03-21       Impact factor: 3.117

2.  Long-term outcomes of myopic choroidal neovascularisation treated with combined ranibizumab and dexamethasone characterised by multi-modal imaging.

Authors:  Anna C S Tan; Kelvin Teo; Ong Sze Guan; Adrian Koh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-03-12       Impact factor: 3.117

3.  Progression of myopic maculopathy in a Caucasian cohort of highly myopic patients with long follow-up: a multistate analysis.

Authors:  Rosa M Coco-Martin; Minal Belani-Raju; Daniel de la Fuente-Gomez; María R Sanabria; Itziar Fernández
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-06-20       Impact factor: 3.117

4.  Inhibition of Obtusifolin on retinal pigment epithelial cell growth under hypoxia.

Authors:  Li-Fei Wang; Zhong-Yang Yan; Ya-Lin Li; Yan-Hui Wang; Sheng-Juan Zhang; Xin Jia; Lu Lu; Yan-Xia Shang; Xin Wang; Yun-Huan Li; Shan-Yu Li
Journal:  Int J Ophthalmol       Date:  2019-10-18       Impact factor: 1.779

5.  Visualizing Structure and Vascular Interactions: Macular Nonperfusion in Three Capillary Plexuses.

Authors:  Justin J Park; Christopher S Chung; Amani A Fawzi
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2018-11-01       Impact factor: 1.300

6.  Predictive factors for postoperative visual acuity improvement with ICL-V4c for ultrahigh myopia above - 10 D.

Authors:  Xiong Ying; Yu Li; Fengju Zhang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-24       Impact factor: 3.535

Review 7.  Current and emerging treatment options for myopic choroidal neovascularization.

Authors:  Leila El Matri; Ahmed Chebil; Fedra Kort
Journal:  Clin Ophthalmol       Date:  2015-04-24

8.  Risk factors for myopic choroidal neovascularization-related macular atrophy after anti-VEGF treatment.

Authors:  Ki Woong Bae; Dong Ik Kim; Bo Hee Kim; Baek-Lok Oh; Eun Kyoung Lee; Chang Ki Yoon; Un Chul Park
Journal:  PLoS One       Date:  2022-09-22       Impact factor: 3.752

9.  LONG-TERM OUTCOMES OF RANIBIZUMAB TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION IN EAST-ASIAN PATIENTS FROM THE RADIANCE STUDY.

Authors:  Nikolle W Tan; Kyoko Ohno-Matsui; Hyoung J Koh; Yoshimi Nagai; Montse Pedros; Rita L Freitas; Wayne Macfadden; Timothy Y Lai
Journal:  Retina       Date:  2018-11       Impact factor: 4.256

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.